Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
brain  	brain  	 NN	B-NP
metastases  	metastases  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
HER2+  	HER2+  	 CD	B-NP
breast  	breast  	 NN	O
cancer  	cancer  	 NN	O
Brain  	Brain  	 NNP	O
metastases  	metastases  	 NNS	O
are  	are  	 VBP	O
a  	a  	 DT	O
frequent  	frequent  	 JJ	O
complication  	complication  	 NN	B-NP
of  	of  	 IN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
effective  	effective  	 JJ	O
treatments  	treatments  	 NNS	O
are  	are  	 VBP	O
available 	available 	 JJ	O
.  	.  	 .	O
This  	This  	 DT	O
article  	article  	 NN	O
aims  	aims  	 VBZ	O
to  	to  	 TO	O
review  	review  	 VB	O
clinical  	clinical  	 JJ	B-NP
aspects  	aspects  	 NNS	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
brain  	brain  	 NN	O
metastases  	metastases  	 VBZ	O
discussing  	discussing  	 VBG	O
the  	the  	 DT	O
various  	various  	 JJ	O
treatment  	treatment  	 NN	B-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	O
such  	such  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
It  	It  	 PRP	O
will  	will  	 MD	O
address  	address  	 VB	O
the  	the  	 DT	O
importance  	importance  	 NN	O
and  	and  	 CC	O
significance  	significance  	 NN	B-NP
of  	of  	 IN	I-NP
brain  	brain  	 NN	I-NP
metastases  	metastases  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
breast  	breast  	 JJ	O
cancer  	cancer  	 NN	O
and 	and 	 CC	O
,  	,  	 ,	O
finally 	finally 	 RB	O
,  	,  	 ,	O
review  	review  	 VB	O
the  	the  	 DT	O
problem  	problem  	 NN	O
of  	of  	 IN	O
brain  	brain  	 NN	O
metastasis  	metastasis  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
human  	human  	 JJ	O
epidermal  	epidermal  	 JJ	B-NP
growth  	growth  	 NN	I-NP
factor  	factor  	 NN	I-NP
receptor  	receptor  	 NN	I-NP
2-positive  	2-positive  	 NNP	O
( 	( 	 -LRB-	O
HER2+ 	HER2+ 	 NNP	B-NP
)  	)  	 -RRB-	O
breast  	breast  	 NN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
With  	With  	 IN	O
ever-improving  	ever-improving  	 JJ	O
survival  	survival  	 NN	B-NP
rates  	rates  	 NNS	I-NP
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
there  	there  	 EX	O
is  	is  	 VBZ	O
a  	a  	 DT	O
greater  	greater  	 JJR	O
likelihood  	likelihood  	 NN	O
that  	that  	 IN	O
many  	many  	 JJ	O
will  	will  	 MD	O
develop  	develop  	 VB	O
brain  	brain  	 NN	B-NP
metastases 	metastases 	 NN	I-NP
.  	.  	 .	O
Treatments  	Treatments  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
whole  	whole  	 JJ	O
brain  	brain  	 NN	O
or  	or  	 CC	O
stereotactic  	stereotactic  	 JJ	B-NP
radiotherapy  	radiotherapy  	 NN	I-NP
and  	and  	 CC	O
surgery  	surgery  	 NN	O
have  	have  	 VBP	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
effective  	effective  	 JJ	O
against  	against  	 IN	O
brain  	brain  	 NN	B-NP
metastases 	metastases 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
HER2+  	HER2+  	 CD	B-NP
breast  	breast  	 NN	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
trastuzumab  	trastuzumab  	 NN	B-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
very  	very  	 RB	O
effective 	effective 	 JJ	O
,  	,  	 ,	O
although  	although  	 IN	O
it  	it  	 PRP	O
cannot  	cannot  	 RB	O
cross  	cross  	 VB	O
the  	the  	 DT	O
blood-brain  	blood-brain  	 JJ	B-NP
barrier 	barrier 	 NN	I-NP
.  	.  	 .	O
If  	If  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
breast  	breast  	 JJ	O
cancer  	cancer  	 NN	O
who  	who  	 WP	O
are  	are  	 VBP	O
being  	being  	 VBG	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 NN	B-NP
and  	and  	 CC	O
are  	are  	 VBP	O
responding  	responding  	 VBG	O
systemically 	systemically 	 NN	O
,  	,  	 ,	O
develop  	develop  	 VB	O
brain  	brain  	 NN	B-NP
metastases 	metastases 	 NN	I-NP
,  	,  	 ,	O
then  	then  	 RB	O
patient  	patient  	 JJ	O
prognosis  	prognosis  	 NN	O
does  	does  	 VBZ	O
need  	need  	 NN	O
to  	to  	 TO	O
be  	be  	 VB	O
taken  	taken  	 VBN	O
into  	into  	 IN	O
account 	account 	 NN	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
maintaining  	maintaining  	 VBG	B-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
trastuzumab  	trastuzumab  	 NN	B-NP
while  	while  	 IN	O
using  	using  	 VBG	O
available  	available  	 JJ	O
therapies  	therapies  	 NNS	O
to  	to  	 TO	O
treat  	treat  	 VB	O
intracranial  	intracranial  	 JJ	B-NP
lesions  	lesions  	 NNS	I-NP
should  	should  	 MD	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
option 	option 	 NN	O
.  	.  	 .	O
